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Colchicine-induced leukopenia usually occurrs in intentional
or accidental overdoses or inappropriate use in combination
with intravenous and oral colchine; however, there have been
several reports of hematologic toxicity in short-term and
small-dose colchicine medication courses. We present two
cases of leukopenia induced by colchicine use concurrent
with immunosuppressants in Behçet's disease. We postulate
that the mechanism of colchicine-induced leukopenia might be
the destruction of circulating leukocytes and an inhibition of
leukocyte production by the immediate and direct toxic effect
of colchicine on idiosyncrasies unique to each patient. The
concurrently administered immunosuppressant might decrease
the threshold for hematologic toxicity of colchicine in the
leukocytes and their precursor cells.
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Sir, Behçet's disease (BD) is rec urrent and long
standing inflammatory disease whic h is hard to
c ontrol in some patients. Colc hic ine appears to be
a promising and safe drug for BD with infrequent
or minor side effec ts.
1 Common side effec ts of
c olc hic ine inc luding diarrhea and gastrointestinal
upset are mild and self-limited, however, severe
reac tions like leukopenia, aplasticanemia, c onfu-
sion, azoospermia, alopec ia, myopathy and
c horea-like syndrome may oc c ur.
2 We present two
c ases of ac ute leukopenia after short-term use of
c olc hic ine in BD patients who were c onc urrently
taking immunosuppresants.
A 58-year-old Korean woman (c ase 1) who had
been taking prednisolone and azathioprine for
two years and a 71-year-old Korean woman (c ase
2) who had been taking methotrexate for three
years. Both of them were diagnosed as inc omplete
type BD ac c ording to RCJ Criteria.
3 Oral c olc hic ine
(1.2 mg per day) was added to alleviate muc oc u-
taneous symptoms, and leukopenia was disc overed
after adding oral c olc hic ine, on 14th days in the
first patient and 3rd days in the sec ond patient.
However, blood c ell c ounts of both patients were
rec overed after c essation of c olc hine and
immunosuppresants with c onservative treatment
with G-CSF (Table 1). In c ase 2, neither c olc hic ine
nor immunosuppresant administered afterward
and her symptoms are well c ontrolled only with
sulfasalazine, ac ec lofenac and topic al dexaltin
c urrently. On the other hand, in c ase 1,
prednisolone, analgesic s and azathioprine were
restarted 5 months later due to intrac table BD,
and regular laboratory studies showed no
abnormalities. Uveitis and aphthous ulc er of the
patient were not well c ontrolled at that time, so
oral c olc hic ine (1.2 mg per day) was added to her
regimen again. Ten days after adding c olc hic ine,
the patient was readmitted due to septicshoc k
and leukopenia and she was died despite intensive
c are.
It is assumed that c olc hic ines was c losely related
in leukopenia of both patients even though the
dose was small and the duration of c olc hic ine use
was short. Our patients had rec eived immuno-
suppressant drugs for a few years without
c omplic ations before taking c olc hic ine, and the
prompt disc ontinuation of c olc hic ine resulted in
rec overy of the leukoc yte c ount in both patients. In
addition, the leukopenicevent was repeated after
the re-initiation of c olc hic ine therapy in c ase 1.
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It is hard to c onc lude that leuc openia was c aused
by inhibiting mic rotubule assembly in mitosis by
c olc hic ine bec ause the dose of c olc hic ine was too
small and leukopenia developed very rapidly after
Table 1. Blood Cell Count in the Patient of Case 1 (A) and Case 2 (B)
(A)
Date Day* WBC (/mm
3) Hb/hc t (g/dL, %) Platelet (× 1000/mm
3)
2004. 09. 30 9130 12.8 (38.2) 215
2004. 11. 16 Day 0 Colc hic ine started
2004. 11. 23 Day 7 3190 12.2 (36.7) 124
2004. 11. 30 Day 14 1000 11.2 (33.7) 46
Colc hic ine, azathioprine quitted
2004. 12. 07 Day 22 500 9.2 (25.1) 110
2004. 12. 20 Day 35 4540 9.1 (25.1) 362
2005. 02. 22 2940 12.2 (36.5) 138
2005. 04. 04 5340 12.8 (40.0) 203
2005. 04. 12 Azathioprine restarted
2005. 05. 10 4350 12.8 (38.9) 208
2005. 06. 05 Day 0 Colc hic ine restarted
2005. 06. 15 Day 10 910 10.0 (29.2) 43
2005. 06. 29 Day 24 550 9.3 (28.2) 23
*the Day from Colc hic ine Started.
(B)
Date Day* WBC (/mm
3) Hb/hc t (g/dL, %) Platelet (x1000/mm
3)
2005. 08. 23 Colc hic ine started
2005. 08. 25 Day 2 1220 8.6 (26.5) 43
Colc hic ine, methotrexate quitted
2005. 08. 27 Day 4 380 6.8 (19.5) 13
2005. 09. 10 Day 18 5870 9.8 (28.6) 373
Table 2. Blood Cell Count in the Patient of Case 2
Date Day* WBC (/mm
3) Hb/hc t (g/dL, %) Platelet (× 1000/mm
3)
2005 .08. 23 Colc hic ine started
2005. 08. 25 Day 2 1220 8.6 (26.5) 43
Colc hic ine, methotrexate quitted
2005. 08. 27 Day 4 380 6.8 (19.5) 13
2005. 09. 10 Day 18 5870 9.8 (28.6) 373
*the day from Colc hic ine started.Two Cases of Acute Leukopenia Induced by Colchicine with Concurrent Immunosuppressants use in Behçet’s Disease
Yonsei Med J Vol. 49, No. 1, 2008
the administration.
2 Bone marrow c ellularities and
leukoc yte c ounts were dec reased and leukoc ytes
with abnormal morphology appeared in peripheral
blood in both of our patients. So the immediate
destruc tion of leukoc ytes with an ac c ompanying
inhibition of leukoc yte produc tion might have
been c aused by the direc t toxiceffec t of c olc hic ines
and it c ould be the mec hanism of c olc hic ine-
induc ed ac ute leukopenia superimposed on idio-
sync rasies. Proposed mec hanisms of ac ute
c olc hic ine-induc ed leukopenia were dec reased
c learanc e of the drug in the patients with
underlying hepatic or renal dysfunc tion, drug
interac tion of c olc hic ine with some drugs whic h
inhibit P-glyc oprotein, and c onc urrent viral
infec tion.
4,5 However, our patients did not have any
evidenc e of hepaticdysfunc tion, renal dysfunc tion
or usage of drugs whic h inhibit P-glyc oprotein.
And serologictests for c ytomegalovirus, rubella
virus, measles virus, Ebstein-Barr virus, human
immunodefic ienc y virus and varic ella zoster virus
were negative. We propose that immunosuppre-
sants might dec rease the threshold for the
idiosync raticreac tion of c olc hic ine in leukoc ytes
and prec ursor c ells. In fac t, it is well known that
those c ells whic h are c hronic ally exposed to
immunosuppressant are vulnerable to the toxic ity
of other drugs and infec tions, and also the
c onc entration of c olc hic ine and immunosuppresants
of the leukoc ytes and prec ursor c ells are higher
than the c onc entration of serum due to muc h
slower c learanc e of the c ompound.
6,7
We share our c ase to highlight c olc hic ines use in
the patients taking immunosuppressant c an induc e
ac ute leukopenia whic h is ac ute, unpredic table and
may be irreversible and life-threatening. We propose
that any patient who is treated with c olc hic ine may
be at risk of hematologictoxic ity and should be
monitored frequently, espec ially in c ase of
c onc urrently using immunosuppressants as well as
other drugs known to have interac tions with
c olc hic ine. In addition, prompt administration of
G-CSF must be c onsidered in the patient with
c olc hic ine-induc ed leukopenia, bec ause the admi-
nistration of G-CSF is known to be very useful and
effec tive treatment regardless of whether c olc hic ine-
induc ed leukopenia is c aused by overdose or
long-term treatment or an idiosync raticreac tion.
8,9
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